Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

C2362F mutation gives rise to an ADAMTS13-resistant von Willebrand factor

View through CrossRef
Summaryvon Willebrand factor (VWF) multimers result from proteolysis by the metalloprotease ADAMTS13. Since C2362F-VWF features abnormally large multimers with their triplet oligomer structure replaced by a diffuse smear, we explored the susceptibility of C2362F-VWF to ADAMTS13. VWF-enriched blood samples, obtained by cryoethanol precipitation of plasma from a patient with von Willebrand disease (VWD) homozygous for the C2362F mutation and a normal subject, were submitted to cleavage by recombinant ADAMTS13 under static conditions in the presence of urea. C2362F-VWF proved completely ADAMTS13-resistant in vitro. At any concentration of recombinant ADAMTS13 (from 0.1 μM to 1 μM), there was no evidence of the abnormally large VWF multimers of C2362F-VWF disappearing, nor any increased representation of triplet multimer bands, unlike the situation seen in normal VWF. This is due partly to a defective ADAMTS13 binding to C2362F-VWF under static conditions, as seen in both the patient’s and recombinant mutated VWF proteins. These findings were associated with a significantly shorter than normal survival of C2362F-VWF after DDAVP, demonstrating that proteolysis and VWF survival may be independent phenomena. Our findings clearly demonstrate that the loss of cysteine 2362 makes VWF resistant to proteolysis by ADAMTS13, at least partly due to an impaired ADAMTS13 binding to VWF. This suggests that the B2 domain of VWF is involved in modulating ADAMTS13 binding to VWF and the consequent proteolytic process. The C2362F-VWF mutation also enables a new abnormality to be identified in the VWF-ADAMTS13 relationship, i.e. an ADAMTS13-resistant VWF.
Title: C2362F mutation gives rise to an ADAMTS13-resistant von Willebrand factor
Description:
Summaryvon Willebrand factor (VWF) multimers result from proteolysis by the metalloprotease ADAMTS13.
Since C2362F-VWF features abnormally large multimers with their triplet oligomer structure replaced by a diffuse smear, we explored the susceptibility of C2362F-VWF to ADAMTS13.
VWF-enriched blood samples, obtained by cryoethanol precipitation of plasma from a patient with von Willebrand disease (VWD) homozygous for the C2362F mutation and a normal subject, were submitted to cleavage by recombinant ADAMTS13 under static conditions in the presence of urea.
C2362F-VWF proved completely ADAMTS13-resistant in vitro.
At any concentration of recombinant ADAMTS13 (from 0.
1 μM to 1 μM), there was no evidence of the abnormally large VWF multimers of C2362F-VWF disappearing, nor any increased representation of triplet multimer bands, unlike the situation seen in normal VWF.
This is due partly to a defective ADAMTS13 binding to C2362F-VWF under static conditions, as seen in both the patient’s and recombinant mutated VWF proteins.
These findings were associated with a significantly shorter than normal survival of C2362F-VWF after DDAVP, demonstrating that proteolysis and VWF survival may be independent phenomena.
Our findings clearly demonstrate that the loss of cysteine 2362 makes VWF resistant to proteolysis by ADAMTS13, at least partly due to an impaired ADAMTS13 binding to VWF.
This suggests that the B2 domain of VWF is involved in modulating ADAMTS13 binding to VWF and the consequent proteolytic process.
The C2362F-VWF mutation also enables a new abnormality to be identified in the VWF-ADAMTS13 relationship, i.
e.
an ADAMTS13-resistant VWF.

Related Results

Abstract 2641: Plasma Von Willebrand Factor and ADAMTS13 Concentrations in Atrial Fibrillation
Abstract 2641: Plasma Von Willebrand Factor and ADAMTS13 Concentrations in Atrial Fibrillation
Background : Von Willebrand factor (VWF) is released from damaged endothelium, and has a role in platelet aggregation through a receptor on the platelet surface. A meta...
Adamts-13 Inhibitor Testing Is Often Negative on Initial Testing
Adamts-13 Inhibitor Testing Is Often Negative on Initial Testing
Abstract Background: Thrombotic thrombocytopenic purpura (TTP) presents with microangiopathic hemolytic anemia and thrombocytopenia and is caused by s...
A Moderate Decrease in ADAMTS13 Activity Correlates with the Severity of STEC-HUS
A Moderate Decrease in ADAMTS13 Activity Correlates with the Severity of STEC-HUS
Atypical hemolytic uremic syndrome (HUS) develops as a result of damage to the endothelium of microvasculature vessels by Shiga toxin produced by enterohemorrhagic Escherichia coli...
«ADAMTS13 – VON WILLEBRAND FACTOR – PLATELETS» SYSTEM IN ATYPICAL HEMOLYTIC UREMIC SYNDROME IN CHILDREN
«ADAMTS13 – VON WILLEBRAND FACTOR – PLATELETS» SYSTEM IN ATYPICAL HEMOLYTIC UREMIC SYNDROME IN CHILDREN
Atypical hemolytic uremic syndrome (aHUS) is an orphan disease caused by hyperactivation of the alternative complement pathway. Objective of the study: to assess the state of the «...
Von Willebrand Disease
Von Willebrand Disease
Von Willebrand disease is a hereditary bleeding disorder caused by a deficiency of von Willebrand factor. The prevalence of von Willebrand disease is estimated to range from approx...
Obstetric and perinatal risks in patients with von Willebrand disease
Obstetric and perinatal risks in patients with von Willebrand disease
This lecture is devoted to a common inherited hemorrhagic disorder, von Willebrand disease (vWD). The article presents the history of the discovery of vWD, the structure and functi...
Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma
Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma
Background: The B-type rafkinase (BRAF) V600E gene mutation plays an important role in the pathogenesis, diagnosis, and prognosis of thyroid carcinoma. This study was conducted to ...

Back to Top